- HK$3.55bn
- HK$3.60bn
- CNY1.47bn
- 52
- 18
- 25
- 18
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,080 | 1,100 | 1,515 | 1,624 | 1,474 |
Cost of Revenue | |||||
Gross Profit | 164 | 111 | 364 | 337 | 247 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,164 | 1,233 | 1,587 | 1,652 | 1,664 |
Operating Profit | -84 | -133 | -72.2 | -28.6 | -190 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -315 | -321 | -582 | -710 | -218 |
Provision for Income Taxes | |||||
Net Income After Taxes | -304 | -326 | -598 | -696 | -223 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -301 | -317 | -599 | -701 | -220 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -301 | -317 | -599 | -701 | -220 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.516 | -0.541 | -0.805 | -1.16 | -0.39 |